U.S. markets close in 1 hour 2 minutes

MEI Pharma, Inc. (MEIP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.9600-0.0700 (-2.31%)
As of 2:58PM EST. Market open.

MEI Pharma, Inc.

11455 El Camino Real
San Diego, CA 92130
United States
858 369 7100
http://www.meipharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Dr. Daniel P. GoldPres, CEO & Director1.14MN/A1954
Mr. Brian G. Drazba B.A., CPA, CPACFO & Sec.603kN/A1961
Mr. David M. Urso B.A., Esq., J.D.COO & Gen. Counsel718.75kN/A1964
Dr. Robert D. MassChief Medical Officer294.59kN/A1954
Mr. David A. Walsey J.D., L.L.M.VP of IR & Corp. CommunicationsN/AN/AN/A
Mr. Brian T. PowlSr. VP of MarketingN/AN/AN/A
Dr. Ofir MorenoSr. VP of Pharmaceutical SciencesN/AN/AN/A
Dr. Karen E. Potts Ph.D.Sr. VP of Regulatory AffairsN/AN/A1963
Dr. Richard G. GhalieSr. VP of Clinical Devel.N/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.

Corporate Governance

MEI Pharma, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 5. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.